Share

August 30, 2016; 87 (9 Supplement 2) Article

Pediatric optic neuritis

E. Ann Yeh, Jennifer S. Graves, Leslie A. Benson, Evangeline Wassmer, Amy Waldman
First published August 29, 2016, DOI: https://doi.org/10.1212/WNL.0000000000002822
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
3236

Share

Article Information

vol. 87 no. 9 Supplement 2 S53-S58
DOI: 
https://doi.org/10.1212/WNL.0000000000002822
PubMed: 
27572862
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received August 19, 2015
  • Accepted in final form January 12, 2016
  • First Published August 29, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. E. Ann Yeh, MD,
    2. Jennifer S. Graves, MD,
    3. Leslie A. Benson, MD,
    4. Evangeline Wassmer, MD and
    5. Amy Waldman, MD
  1. E. Ann Yeh, MD,
    2. Scientific Advisory Boards:

    1. I perform MS relapse adjudication for ACI services on a fee-for-service basis.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurology, editorial advisory board, 2013-present.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1) CIHR, Co-I. PI: Pohl 2) PCORI, Co-I, CE-1304-7079 3) CMSMS (CIHI/PHAC), MS Monitoring system pilot funding

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) National MS Society HC 0148 2) National MS Society PP2256 3) MS Society (Canada) 4) Dairy Farmers of Ontario 5) SickKids Innovation Fund 6) MS Research Foundation (Canada) 7) Rare Diseases Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Jennifer S. Graves, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. S3 Group Advance Medical Group

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1) NIH BIRCWH K12 Program (5K12HD052163), investigator, 2013-2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) Foundation for the Consortium of Multiple Sclerosis Centers 2) Race to Erase MS Foundation 3) National MS Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Leslie A. Benson, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Boston Children's Hospital office of faculty development fellowship grant

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Evangeline Wassmer, MD and
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Evangeline Wassmer received honoraria for speaking / travel costs from BiogenIdec, Teva, Genzyme, Shire, UCB, and Merck Serono. She is an investigator in trials with BiogenIdec, Sanofi and Novartis. Her MS research projects have been funded by the UK MS Society, Action Medical Research and Birmingham Children?s Hospital Research Foundation.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Attended meetings (CME) supported by many pharmaceutical companies. Her MS research projects have been funded by the UK MS Society, Action Medical Research and Birmingham Children?s Hospital Research Foundation.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Amy Waldman, MD
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis Pharmaceutical Corporation: reimbursement for travel to an advisory board meeting.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. (1) Sjogren-Larsson Syndrome, UpToDate, 2007-present (2) Pelizaeus-Merzbacher Disease, UpToDate, 2007-present (3) Alexander Disease, UpToDate, 2007-present (4) Leukoencephalopathy due to heroin inhalation (chasing the dragon), UpToDate, 2007-present (5) Cerebrotendinous xanthomatosis, UpToDate, 2007- present (6) Vanishing white matter disease, UpToDate, 2007- present (7) Acute disseminated encephalomyelitis, UpToDate, 2014- present

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) NIH Loan Repayment Program

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen Idec

    Research Support, Government Entities:

    1. (1) NIH/NINDS, K23NS069806, PI, 2012-2017 (2) NIH/NINDS, R01NS071463, site PI, 2011-2016

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. (1) Pfizer (2) Spark Therapeutics

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Division of Neurology (E.A.Y.), Hospital for Sick Children, Hospital for Sick Children Research Institute, Department of Pediatrics, University of Toronto, Ontario, Canada; Department of Neurology (J.S.G.), University of California, San Francisco; Department of Neurology (L.A.B.), Boston Children's Hospital, Boston, MA; Department of Neurology (E.W.), Birmingham Children's Hospital, Birmingham, UK; and Department of Neurology (A.W.), The Children's Hospital of Philadelphia, PA.
  1. Correspondence to Dr. Yeh: ann.yeh{at}sickkids.ca
View Full Text

Article usage

Article usage: August 2016 to November 2019

AbstractFullPdfSource
Aug 20164061056Highwire
Sep 2016982192221Highwire
Oct 2016317143102Highwire
Nov 20162238785Highwire
Dec 20161185744Highwire
Jan 201717011471Highwire
Feb 20171686073Highwire
Mar 20171416689Highwire
Apr 2017985153Highwire
May 20171185466Highwire
Jun 2017796663Highwire
Jul 2017675765Highwire
Aug 2017785367Highwire
Sep 2017676567Highwire
Oct 2017827670Highwire
Nov 20175165114Highwire
Dec 2017113392Highwire
Jan 2018311791Highwire
Feb 2018420365Highwire
Mar 2018123160Highwire
Apr 2018224556Highwire
May 2018533282Highwire
Jun 20182310116Highwire
Jul 2018617166Highwire
Aug 2018216981Highwire
Sep 2018117691Highwire
Oct 20184272128Highwire
Nov 2018324168Highwire
Dec 2018424164Highwire
Jan 2019733287Highwire
Feb 2019725772Highwire
Mar 20191334479Highwire
Apr 2019730881Highwire
May 20191522387Highwire
Jun 20191820395Highwire
Jul 20193217974Highwire
Aug 20191516677Highwire
Sep 20191417970Highwire
Oct 20191617976Highwire
Nov 20191519372Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me